Experiment 588517
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | SEIDMAN,AD: PORTENOY,R: YAO,TJ: LEPORE,J: MONT,EK: KORTMANSKY,J: ONETTO,N: REN,L: GRECHKO,J: BELTANGADY,M: USAKEWICZ,J: SOUHRADA,M: HOUSTON,C: MC CABE,M: SALVAGGIO,R: THALER,H: NORTON,L:. (1995). QUALITY OF LIFE IN PHASE II TRIALS: A STUDY OF METHODOLOGY AND PREDICTIVE VALUE IN PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH PACLITAXEL PLUS GRANULOCYTE COLONY-STIMULATING FACTOR.. 87(17) |
| Amount utilized | |
| Compound isolated | |
| Disease | STUDY EVALUTING UTILITY OF QUALITY-OF-LIFE ASSESSMENT IN TWO PHASE II CLINICAL TRIALS OF PATIENTS RECEIVING PACLITAXEL AND RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR FOR METASTATIC BREAST CARCINOMA. COMBINATION OF QUALITY-OF-LIFE ASSESSMENTS WITH EXTENT OF DISEASE PREDICTED SURVIVAL MORE ACCURATELY THAN EITHER SEPARATELY. |
| Dose amount | 200.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M |
| Dose expression | DOSE |